• BAPTA-AM: Practical Calcium Chelation Workflows

  2026-08-14

  BAPTA-AM is a cell-permeable calcium chelator for reducing free intracellular Ca²⁺ during calcium-signaling, imaging, injury, and apoptosis workflows. It should be used as an experimentally controlled calcium-buffering tool, not as a pathway-specific inhibitor or clinical treatment, because membrane loading, magnesium interference, optical behavior, and ion-channel effects can influence the phenotype.

• Sisomicin, Netilmicin and Dibekacin: 1984 Review

  2026-08-13

  This 1984 review compared the antibacterial spectra, resistance mechanisms, pharmacokinetics, toxicity, and clinical use of Sisomicin, netilmicin, and dibekacin. Its central contribution was to connect structural modifications and resistance-enzyme profiles with comparative activity against clinically important Gram-negative organisms, while emphasizing renal monitoring and the limits of extrapolating in vitro activity to treatment outcomes.

• Phytol and RXR Signaling: Translational Strategy

  2026-08-13

  Phytol offers translational researchers a useful but deliberately non-reductionist model for studying retinoid X receptor signaling, nuclear hormone receptor activation, and pathway cross-talk. This article combines assay strategy, product-quality considerations, and a cautiously framed materials-science perspective to show how mechanistic ambition can be matched with experimental discipline.

• Firefly Luciferase mRNA for LNP Assays

  2026-08-12

  Use Firefly Luciferase mRNA as a sensitive, transient readout for comparing mRNA delivery, translation, and cell responses. This workflow combines Cap1 capping, 5-moUTP modification, and an optimized poly(A) tail with practical controls for reproducible cell-based and in vivo imaging studies.

• Ibrexafungerp in Fluconazole-Resistant C. auris

  2026-08-12

  Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using broth microdilution and a delayed-treatment neutropenic mouse model. The study found consistent in vitro activity and improved survival and kidney fungal-burden outcomes with ibrexafungerp, supporting further investigation of an orally active glucan-synthesis inhibitor for invasive candidiasis.

• COG133, miR-146a, and Diabetic Wound Healing

  2026-08-11

  The reference study identifies the ApoE-mimetic peptide COG133 as a potential dual-action candidate for diabetic wound research, combining effects on human diabetic dermal fibroblast behavior with antibacterial and antibiofilm activity. COG133 enhanced fibroblast migration, increased miR-146a expression, reduced IL-6 and ApoE expression, and decreased Pseudomonas aeruginosa PAO1 biofilm formation, while leaving viability, NF-κB, and TRAF6 unchanged.

• Drug Response Metrics in Cancer In Vitro

  2026-08-10

  Hannah Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework for separating proliferative arrest from cell killing, improving interpretation of drug-response experiments and the design of translational cancer biology studies.

• Cyclic Pifithrin-α hydrobromide Workflow Guide

  2026-08-08

  Cyclic Pifithrin-α hydrobromide is a practical p53 inhibitor for separating p53-dependent apoptosis, growth arrest, and DNA-damage responses from pathway-independent toxicity. This guide connects cancer-cell assays with an exploratory neuroinflammation workflow while emphasizing solvent control, matched genetic controls, and assay-specific validation.

• Protease Inhibitor Cocktail for Phospho-Signaling

  2026-08-07

  Discover how a Protease Inhibitor Cocktail EDTA-Free protects signaling-state measurements from preanalytical proteolysis. This guide connects K1007 with SHP2–MAPK and PI3K–AKT research, showing how inhibitor selection, controls, and workflow timing affect assay interpretation.

• ZK53: A Potent Human Mitochondrial Serine Protease ClpP Acti

  2026-08-07

  ZK53 stands out as a highly selective activator of human mitochondrial ClpP, enabling direct disruption of tumor cell metabolism and cell cycle progression with minimal off-target effects. Its robust efficacy across in vitro and in vivo cancer models, alongside clear workflow advantages, makes it a next-generation tool for researchers targeting mitochondrial dysfunction.

• Pol II Degradation Triggers Apoptosis Independently of Trans

  2026-08-06

  A recent study demonstrates that targeted degradation of RNA polymerase II (Pol II) can initiate apoptosis in tumor cells through a mechanism independent of global transcriptional shutdown. These findings reveal new mechanistic insights into cell death signaling and have significant implications for the development and assessment of apoptosis-targeting agents in cancer research.

• Pyridostatin TFA: A Strategic Catalyst for G-Quadruplex Rese

  2026-08-06

  Pyridostatin TFA is revolutionizing translational research into G-quadruplex biology, bridging cancer and neurodegeneration studies with mechanistic insight and practical guidance. This article offers an in-depth, evidence-driven perspective on leveraging Pyridostatin as a selective G-quadruplex stabilizer, explores its role in modulating telomere function and protein aggregation, and provides actionable protocol parameters to maximize experimental impact.

• Dietary Arachidonic Acid Enhances Vaccine-Induced Humoral Im

  2026-08-05

  This study demonstrates that dietary arachidonic acid (ARA) supplementation accelerates and amplifies humoral immunity post-vaccination, both in animal models and human subjects. The mechanistic findings highlight the role of ARA metabolites in activating B cells, presenting a potential nutritional strategy for rapid vaccine-induced protection.

• Gentamycin Sulfate in Protein Synthesis & Resistance Modelin

  2026-08-05

  Gentamycin Sulfate stands as a pivotal aminoglycoside antibiotic for dissecting bacterial protein synthesis and modeling antibiotic resistance. This article provides real-world workflows, protocol optimization, and troubleshooting tips for advanced applications in Gram-negative infection research.

• Protease Inhibitor Cocktail EDTA-Free: Mechanistic Precision

  2026-08-04

  Explore the advanced mechanism and assay-critical value of the Protease Inhibitor Cocktail EDTA-Free (100X in DMSO). This article reveals how scientific insights into lysosomal repair inform precise inhibitor selection for sensitive protein workflows.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page